Eighteen male U.S. veterans meeting DSM-III criteria for posttraumatic
stress disorder (PTSD) completed a 4-week double-blind, crossover study
comparing administration of 200 mg/day of desipramine with placebo.
Response was measured by using the Beck Depression Inventory, the Hamilton
Rating Scale for Depression, the Hamilton Rating Scale for Anxiety, and the
Impact of Event Scale. Overall, the only apparent response to desipramine
was in some symptoms of depression; there were no changes in anxiety and
other PTSD symptoms.